Listar por autor "Sánchez- Rovira, P"
Mostrando ítems 1-2 de 2
-
A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression
Ribelles, Nuria; López-Siles, J; Sánchez-Muñoz, Alfonso
; Sánchez, E; González, E; Sánchez, MJ; Carabantes, F; Sánchez- Rovira, P; Márquez, A; Dueñas, R; Sevilla, I; Alba-Conejo, Emilio[et al.] (Bentham Science Publishers Ltd, 2008)
Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU). The ... -
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Albanell, J.; Martínez-García, M.; Ramos-Boyero, Manuel; O'Connor, Miriam; De-la-Cruz-Merino, Luis; Santaballa-Bertrán, Ana; Martínez-Jáñez, Noelia; Moreno-Antón, Fernando; Fernández, Isaura; Alarcón, Jesús Damián; Virizuela-Echaburu, Javier Antonio; De-la-Haba-Rodríguez, Juan Rafael; Sánchez- Rovira, P; González-Cortijo, Lucía; Margelí, Mireia; Sánchez-Muñoz, Alfonso; Antón, A.; Casas, María Isabel; Bezares, Susana; Rojo, Federico[et al.] (Elsevier, 2022)
Background: The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative endocrine-sensitive advanced breast ...